These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17429733)

  • 1. The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis.
    Degertekin B; Ozenirler S; Elbeg S; Akyol G
    Dig Dis Sci; 2007 Oct; 52(10):2622-8. PubMed ID: 17429733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?
    Chitturi S; Farrell G; Frost L; Kriketos A; Lin R; Fung C; Liddle C; Samarasinghe D; George J
    Hepatology; 2002 Aug; 36(2):403-9. PubMed ID: 12143049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
    Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
    Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease.
    Canbakan B; Senturk H; Tahan V; Hatemi I; Balci H; Toptas T; Sonsuz A; Velet M; Aydin S; Dirican A; Ozgulle S; Ozbay G
    Acta Gastroenterol Belg; 2007; 70(3):277-84. PubMed ID: 18074737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study.
    de Lédinghen V; Ratziu V; Causse X; Le Bail B; Capron D; Renou C; Pilette C; Oules V; Gelsi E; Oberti F; Vallet-Pichard A; Le Provost N; Cadranel JF; ;
    J Hepatol; 2006 Oct; 45(4):592-9. PubMed ID: 16837098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis.
    Uraz S; Aygun C; Sonsuz A; Ozbay G
    Dig Dis Sci; 2005 May; 50(5):964-9. PubMed ID: 15906776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between advanced oxidation protein products (AOPP) and biochemical and histopathological findings in patients with nonalcoholic steatohepatitis.
    Ozenirler S; Erkan G; Konca Degertekin C; Ercin U; Cengiz M; Bilgihan A; Yilmaz G; Akyol G
    J Dig Dis; 2014 Mar; 15(3):131-6. PubMed ID: 24528633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between morphological diagnosis of NASH (non-alcoholic steatohepatitis) and liver function tests in a group of patients with morbid obesity].
    Chavarría-Arciniega S; López-Alvarenga JC; Uribe-Uribe NO; Herrera-Hernández M; González-Barranco J
    Rev Invest Clin; 2005; 57(4):505-12. PubMed ID: 16315634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should a liver biopsy be done in patients with subclinical chronically elevated transaminases?
    de Lédinghen V; Combes M; Trouette H; Winnock M; Amouretti M; de Mascarel A; Couzigou P
    Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):879-83. PubMed ID: 15316412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis.
    Arvaniti VA; Thomopoulos KC; Tsamandas A; Makri M; Psyrogiannis A; Vafiadis G; Assimakopoulos SF; Labropoulou-Karatza C
    Acta Gastroenterol Belg; 2008; 71(4):355-60. PubMed ID: 19317274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.
    Yoneda M; Mawatari H; Fujita K; Iida H; Yonemitsu K; Kato S; Takahashi H; Kirikoshi H; Inamori M; Nozaki Y; Abe Y; Kubota K; Saito S; Iwasaki T; Terauchi Y; Togo S; Maeyama S; Nakajima A
    J Gastroenterol; 2007 Jul; 42(7):573-82. PubMed ID: 17653654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.
    Joka D; Wahl K; Moeller S; Schlue J; Vaske B; Bahr MJ; Manns MP; Schulze-Osthoff K; Bantel H
    Hepatology; 2012 Feb; 55(2):455-64. PubMed ID: 21993925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH).
    Hussein O; Grosovski M; Schlesinger S; Szvalb S; Assy N
    Dig Dis Sci; 2007 Oct; 52(10):2512-9. PubMed ID: 17404856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum liver fatty acid binding protein shows good correlation with liver histology in NASH.
    Özenirler S; Degertekin CK; Erkan G; Elbeğ Ş; Tuncer C; Kandilc U; Akyol G
    Hepatogastroenterology; 2013; 60(125):1095-100. PubMed ID: 23803374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alkaline phosphatase: can it be considered as an indicator of liver fibrosis in non-alcoholic steatohepatitis with type 2 diabetes?
    Kocabay G; Telci A; Tutuncu Y; Tiryaki B; Ozel S; Cevikbas U; Okten A; Satman I
    Bratisl Lek Listy; 2011; 112(11):626-9. PubMed ID: 22180989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.